PAXX

Across TCGA pan-cancer cohorts, PAXX mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PAXX data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PAXX mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PAXX expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where PAXX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.943	0.772	.001	36	view →
PDAC	DFS	Median	II,III,IV	0.905	0.659	.003	17	view →
UCEC	OS	Tertile	All	1.000	0.837	.014	4	view →
GBM	DFS	Median	All	0.671	0.762	.025	2	view →
HNSC	DFS	Quartile	All	0.907	1.000	.027	2	view →
LSCC	DFS	Median	II,III,IV	1.000	0.502	.038	2	view →
LUAD	DFS	Median	All	0.804	0.680	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PAXX–CCRCC (OS)

Open the CCRCC breakdown →